Skip to main content

Table 5 Effect-modification of the amikacin or kanamycin exposure and the occurrence of hearing loss in MDR-TB treatment

From: Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort

Variable Strata Stratum-specific crude OR (95 % Confidence Interval) P-value (Breslow-Day test of homogeneity across strata)
Age Age 0–24 years 2.0 (0.4–10.6)  
  Age 25–34 years 2.8 (0.8–9.2) 0.99
  Age 35–44 years 2.6 (0.8–8.2)  
  Age 45+ years 3.0 (0.4–26.4)  
Baseline body weight Weight 18–39 kgs NA  
  Weight 40–59 kgs 2.8 (1.1–6.8) 0.06
  Weight 60+ kgs 1.1 (0.4–3.0)  
Sex Female 1.1 (0.4–3.0) 0.06
  Male 4.5 (1.5–13.4)  
HIV status HIV negative 1.7 (0.7–4.1)  
  HIV positive 3.4 (1.1–10.6) 0.33
  1. Legend: NA not possible to estimate due to some cells having zero values, kgs kilograms, HIV human immunodeficiency virus infection status